Novo Nordisk (NVO) Is Up 2.45% in One Week: What You Should Know
https://www.zacks.com/stock/news/2210353/novo-nordisk-nvo-is-up-2-45-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2210353
Jan 15, 2024 - Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
0
UnitedHealth Group (UNH) Q4 Earnings Beat on Membership Growth
https://www.zacks.com/stock/news/2209723/unitedhealth-group-unh-q4-earnings-beat-on-membership-growth?cid=CS-ZC-FT-analyst_blog|earnings_article-2209723
Jan 12, 2024 - UnitedHealth Group's (UNH) Q4 results benefit on the back of double-digit revenue growth in its UnitedHealthcare and Optum segments. Management maintains its 2024 adjusted EPS target within $27.50-$28.00.
0
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
0
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026
Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
0
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
https://www.zacks.com/stock/news/2208771/want-better-returns-don-t-ignore-these-2-medical-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2208771
Jan 11, 2024 - Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
0
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
https://www.zacks.com/stock/news/2207561/novo-nordisk-s-nvo-phase-iii-diabetes-study-meets-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207561
Jan 09, 2024 - Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
0
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-lly-s-new-digital-pharmacy-nvo-abbv-s-fresh-r-d-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2206363
Jan 05, 2024 - Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
0
The Best Stocks to Invest $1,000 in Right Now
https://www.fool.com/investing/2024/01/04/the-best-stocks-to-invest-1000-in-right-now/?source=iedfolrf0000001
Jan 04, 2024 - It's not too late to get in on these market beaters.
0
Here's Why You Should Invest in Adverum (ADVM) Stock Now
https://www.zacks.com/stock/news/2205527/here-s-why-you-should-invest-in-adverum-advm-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2205527
Jan 04, 2024 - Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.
0